CLINTON, N.J., Jan. 3 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biopharmaceutical company, announced today that its Chairman & CEO, David Shaw, will present at the 26th Annual JPMorgan Healthcare Conference on Tuesday, January 8, 2008 at 3:00 p.m., PST. The conference will be held January 7-10 at The Westin St. Francis Hotel in San Francisco.
About Ikaria Holdings, Inc.
Ikaria Holdings, Inc. is a fully integrated biotherapeutics company
focused on the development and commercialization of innovative in-hospital
pharmaceutical products and drug/device combinations for the critically
ill. The company's product, INOmax(R) (nitric oxide) for inhalation, is an
FDA- approved drug for the treatment of hypoxic respiratory failure in term
and near-term newborns. The drug also is approved by regulatory authorities
and used in Canada, Europe, Australia and Latin America. In addition to
marketing and selling its INOmax product, Ikaria is engaged in both Phase
II trials with Covox(R) (carbon monoxide) for inhalation and Phase I trials
with hydrogen sulfide (H2S) for various indications. Ikaria has a staff of
over 300 people and is headquartered in Clinton, NJ, with research
facilities in Seattle, WA and Madison, WI and manufacturing in Port Allen,
LA. For more information on Ikaria, please visit http://www.ikaria.com.
The Ruth Group
|SOURCE Ikaria Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved